Hematology / Oncology @Point of Care Podcasts Podcast Por @Point of Care arte de portada

Hematology / Oncology @Point of Care Podcasts

Hematology / Oncology @Point of Care Podcasts

De: @Point of Care
Escúchala gratis

Our @Point of Care Hematology & Oncology Podcasts have healthcare experts discussing and providing information related to oncology diagnosis, treatment, management, and other important information.Copyright 2020 At Point of Care, LLC. All rights reserved. Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs
    Jan 15 2026

    In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs).

    Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    31 m
  • S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib
    Jan 15 2026

    In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities.

    Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    29 m
  • S27:E1 – HER2-Directed ADCs in Advanced NSCLC
    Jan 15 2026

    In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates (ADCs) in the management of advanced non-small cell lung cancer. Their engaging discussion will include topics such as HER2 biomarker testing, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated toxicities.

    Visit https://suitehome.atpointofcare.com/library/2720.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    25 m
Todavía no hay opiniones